Shin Nippon Biomedical Laboratories, Ltd. provided consolidated earnings guidance for the year ending March 31, 2023. For the fiscal year ending, the company expected to report revenue of JPY 24,000 million and operating profit of JPY 5,260 million. the expected profit attributable to owners of parent is JPY 7,000 million and profit per share is JPY 168.13.